Whole-genome sequencing and gene network modules predict gemcitabine/carboplatin-induced myelosuppression in non-small cell lung cancer patients
暂无分享,去创建一个
M. Gustafsson | J. Lundeberg | T. V. Badam | Zelmina Lubovac-Pilav | P. Sahlén | R. Lewensohn | H. Gréen | N. Björn | R. Spalinskas | E. Brandén | H. Koyi | L. de Petris
[1] C. Lozzio,et al. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. , 1975, Blood.
[2] C. Lozzio,et al. Properties and usefulness of the original K-562 human myelogenous leukemia cell line. , 1979, Leukemia research.
[3] C. Lozzio,et al. A Multipotential Leukemia Cell Line (K-562) of Human Origin 1 , 1981, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[4] Y. Hayashi,et al. Establishment of a human leukaemic cell line (CMK) with megakaryocytic characteristics from a Down's syndrome patient with acute megakaryoblastic leukaemia , 1989, British journal of haematology.
[5] T. Suda,et al. Growth and differentiation of a human megakaryoblastic cell line, CMK. , 1989, Blood.
[6] Y. Matsuo,et al. Establishment and characterization of a novel megakaryoblastic cell line, MOLM-1, from a patient with chronic myelogenous leukemia. , 1991, Human cell.
[7] K. Tanaka,et al. Structurally altered Evi-1 protein generated in the 3q21q26 syndrome. , 1996, Oncogene.
[8] H. Drexler,et al. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia. , 1999, Leukemia research.
[9] Gary D. Bader,et al. An automated method for finding molecular complexes in large protein interaction networks , 2003, BMC Bioinformatics.
[10] I. Smith,et al. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II , 2004, Cancer Chemotherapy and Pharmacology.
[11] Bart De Moor,et al. BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis , 2005, Bioinform..
[12] J. Robert,et al. Predicting drug response and toxicity based on gene polymorphisms. , 2005, Critical reviews in oncology/hematology.
[13] Michel Eichelbaum,et al. Pharmacogenomics and individualized drug therapy. , 2006, Annual review of medicine.
[14] Manuel A. R. Ferreira,et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.
[15] M. Robinson,et al. A scaling normalization method for differential expression analysis of RNA-seq data , 2010, Genome Biology.
[16] S. Kaasa,et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[18] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[19] E. Birney,et al. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt , 2009, Nature Protocols.
[20] M. DePristo,et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.
[21] T. Ugarova,et al. Plasminogen on the surfaces of fibrin clots prevents adhesion of leukocytes and platelets , 2010, Journal of thrombosis and haemostasis : JTH.
[22] P. Robinson,et al. Whole-exome sequencing for finding de novo mutations in sporadic mental retardation , 2010, Genome Biology.
[23] Richard Durbin,et al. Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..
[24] Charles Auffray,et al. An integrative systems biology approach to understanding pulmonary diseases. , 2010, Chest.
[25] Mark D. Robinson,et al. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..
[26] M. DePristo,et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.
[27] Marcel Martin. Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .
[28] Andrew P Morris,et al. Basic statistical analysis in genetic case-control studies , 2011, Nature Protocols.
[29] Q. Wei,et al. Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. , 2011, Lung cancer.
[30] Sijian Wang,et al. RANDOM LASSO. , 2011, The annals of applied statistics.
[31] Gonçalo R. Abecasis,et al. The variant call format and VCFtools , 2011, Bioinform..
[32] M. Tsuboi,et al. Randomized Phase II Study of Two Schedules of Carboplatin and Gemcitabine for Stage IIIB and IV Advanced Non-Small Cell Lung Cancer (JACCRO LC-01 Study) , 2011, Chemotherapy.
[33] David Levine,et al. A high-performance computing toolset for relatedness and principal component analysis of SNP data , 2012, Bioinform..
[34] Joaquín Dopazo,et al. Qualimap: evaluating next-generation sequencing alignment data , 2012, Bioinform..
[35] Davis J. McCarthy,et al. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation , 2012, Nucleic acids research.
[36] M. Jarvelin,et al. Highly interconnected genes in disease-specific networks are enriched for disease-associated polymorphisms , 2012, Genome Biology.
[37] Q. Wei,et al. Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer. , 2012, The oncologist.
[38] J. Lundeberg,et al. Identification of candidate SNPs for drug induced toxicity from differentially expressed genes in associated tissues. , 2012, Gene.
[39] Yusuke Nakamura,et al. A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy , 2012, Pharmacogenetics and genomics.
[40] Guangchuang Yu,et al. clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.
[41] J. Quigley,et al. Cell Surface Remodeling by Plasmin: A New Function for an Old Enzyme , 2012, Journal of biomedicine & biotechnology.
[42] M. Eileen Dolan,et al. Cancer pharmacogenomics: strategies and challenges , 2012, Nature Reviews Genetics.
[43] Jonathan E. Clark,et al. Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer , 2013, BMC Systems Biology.
[44] Yusuke Nakamura,et al. Genome‐wide association study of chemotherapeutic agent‐induced severe neutropenia/leucopenia for patients in Biobank Japan , 2013, Cancer science.
[45] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[46] Pablo Villoslada,et al. Modules, networks and systems medicine for understanding disease and aiding diagnosis , 2014, Genome Medicine.
[47] R. Rosenfeld. Patients , 2012, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[48] Chun-Ho Shih,et al. A critical role for the regulation of Syk from agglutination to aggregation in human platelets. , 2014, Biochemical and biophysical research communications.
[49] N. Wu,et al. Low Expression of the E3 Ubiquitin Ligase CBL Confers Chemoresistance in Human Pancreatic Cancer and Is Targeted by Epidermal Growth Factor Receptor Inhibition , 2014, Clinical Cancer Research.
[50] Wei Shi,et al. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..
[51] A. Barabasi,et al. Uncovering disease-disease relationships through the incomplete interactome , 2015, Science.
[52] Joakim Lundeberg,et al. Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities , 2015, Clinical Cancer Research.
[53] L. Medeiros,et al. Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1. , 2015, American journal of clinical pathology.
[54] Rémy Bruggmann,et al. Clinical sequencing: is WGS the better WES? , 2016, Human Genetics.
[55] J. Heemskerk,et al. Plasminogen associates with phosphatidylserine-exposing platelets and contributes to thrombus lysis under flow. , 2015, Blood.
[56] Lei Shang,et al. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants , 2014, Proceedings of the National Academy of Sciences.
[57] Qing-Yu He,et al. ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization , 2015, Bioinform..
[58] Albert-László Barabási,et al. A DIseAse MOdule Detection (DIAMOnD) Algorithm Derived from a Systematic Analysis of Connectivity Patterns of Disease Proteins in the Human Interactome , 2015, PLoS Comput. Biol..
[59] L. Donehower,et al. WIP1 Phosphatase as a Potential Therapeutic Target in Neuroblastoma , 2015, PloS one.
[60] K. Stegmaier,et al. Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia , 2015, Oncotarget.
[61] Li'na Hu,et al. Tyrosine kinase LYN is an oncotarget in human cervical cancer: A quantitative proteomic based study , 2016, Oncotarget.
[62] Antonia K. Roseweir,et al. Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients , 2016, BMC Cancer.
[63] Y. Shin,et al. LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients , 2016, OncoTarget.
[64] D. Postma,et al. Paving the way of systems biology and precision medicine in allergic diseases: the MeDALL success story , 2016, Allergy.
[65] Y. Bang,et al. Src as a Therapeutic Target in Biliary Tract Cancer , 2016, Molecular Cancer Therapeutics.
[66] Wen-Lun Wang,et al. Low disabled-2 expression promotes tumor progression and determines poor survival and high recurrence of esophageal squamous cell carcinoma , 2016, Oncotarget.
[67] G. Jin,et al. Genome-wide association study of myelosuppression in non-small-cell lung cancer patients with platinum-based chemotherapy , 2015, The Pharmacogenomics Journal.
[68] Mika Gustafsson,et al. Dynamic Response Genes in CD4+ T Cells Reveal a Network of Interactive Proteins that Classifies Disease Activity in Multiple Sclerosis. , 2016, Cell reports.
[69] Måns Magnusson,et al. MultiQC: summarize analysis results for multiple tools and samples in a single report , 2016, Bioinform..
[70] A. Reiter,et al. Myeloid neoplasms with eosinophilia. , 2017, Blood.
[71] Damian Szklarczyk,et al. The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible , 2016, Nucleic Acids Res..
[72] Reinhard Guthke,et al. ModuleDiscoverer: Identification of regulatory modules in protein-protein interaction networks , 2017, Scientific Reports.
[73] A. Zick,et al. Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients , 2016, Medicine.
[74] Hui-Ju Tsai,et al. Functional links between Disabled‐2 Ser723 phosphorylation and thrombin signaling in human platelets , 2017, Journal of thrombosis and haemostasis : JTH.
[75] P. Sahlén,et al. Comparison of Variant Calls from Whole Genome and Whole Exome Sequencing Data Using Matched Samples , 2018 .
[76] K. Kiwerska,et al. Frequent methylation of DAB2, a Wnt pathway antagonist, in oral and oropharyngeal squamous cell carcinomas. , 2017, Pathology, research and practice.
[77] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[78] J. Lundeberg,et al. Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia , 2019, The Pharmacogenomics Journal.
[79] Mika Gustafsson,et al. MODifieR: an Ensemble R Package for Inference of Disease Modules from Transcriptomics Networks , 2020, Bioinform..